Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches
Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...
BioSpace3h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
Lilly's Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.